medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials

medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials. Liege, Belgium - November 3, 2022: medmix Drug Delivery (Haselmeier) and AARDEX Group announced today a collaboration, combining Haselmeier´s D-Flex™ Logbook with AARDEX Group’s Medication Adherence software and hardware ecosystem.

Jumo Health Honored in Inc.’s Inaugural Power Partner Awards

Jumo Health, a global provider of age appropriate, culturally sensitive medical education resources, today announced it has been recognized by Inc. Magazine in its inaugural Power Partner Awards.

Mayo Clinic, Orbita to Speak on Successful Utilization of Intelligent Virtual Assistants at HCIC

Vaxess Announces $27M in Series B Funding

Vaxess Technologies, Inc., a life sciences company developing a shelf-stable, sustained-release vaccine patch, today announced the closing of its Series B funding.

Creative Enzymes Launches Raw Materials for Manufacturing Diagnostic Kits

Creative Enzymes Expands Its Probiotic Portfolio

BOC Sciences: Peptides Open New Path toward Osteoporosis Treatment

BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas.

BOC Sciences Makes Easy Access to Polymerization Tech

Owing to the continuously upgraded synthesis technologies and analytical abilities, BOC Sciences has performed well in the polymer industry, serving the community with a comprehensive product portfolio and valuable technical support.

Rising Prevalence of Isotope Labeling Carbohydrates Drives Innovations at BOC Sciences

BOC Sciences provides global customers with a range of high-quality stable isotope labeling compounds for biomedical research. It recently announced the availability of labeled carbohydrates, arousing an enthusiastic response from the market.

BOC Sciences: ADC Analysis and Characterization Support Development, Registration, and Release

BOC Sciences announces support for antibody-drug conjugate (ADC) development, registration, and release by providing comprehensive analysis and characterization technologies.

Metatranscriptome Analysis Service Is Now Available at CD Genomics

Meet CD Genomics at the SITC 37th Annual Meeting

Extensive Options for Graphene Quantum Dot Modifications

Pretreatment Chemicals Make Electroplating More Efficient

BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting

BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.

Proscia Presents Study Results On New Artificial Intelligence That Predicts Diagnostic Concordance For Melanoma

Findings illustrate promise of technology to lower misdiagnosis rate for deadliest form of skin cancer

Creative Biogene Develops Custom Lentivirus Services to Support Stable Cell Line Generation

Microbiosci Releases LPS Extraction Service to Support Managing Endotoxins Issues

Nanoparticle Development Services for Drug Delivery System Research

Creative Biogene Delivers Knockout Mouse Models to Support Gene Editing and Future Studies